Breaking Down Kobayashi Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Kobayashi Pharmaceutical's recent results demand scrutiny: revenue fell to ¥165.6 billion in FY2024, down 4.53% as the 'benikoji' health scare triggered recalls and ad suspensions, while the company still forecasts a rebound to ¥171 billion for FY2025 (+3.3%); profitability shows strain with operating income at ¥24.8 billion (-3.6%) and net profit plunging 50.5% to ¥10 billion after an extraordinary loss of ¥12.7 billion tied to recalls and compensation, even as liquidity and balance-sheet metrics remain strong-cash and equivalents of ¥67.28 billion, a current ratio of 3.34, total debt/equity of 0.38, and market cap of ¥395.48 billion; valuation multiples (trailing P/E 36.94, forward P/E 22.53, P/S 2.45) and a dividend yield of 1.67% frame investor expectations amid legal and reputational risks, product relaunches, and R&D-driven growth initiatives-read on for a detailed, number-by-number breakdown to inform your investment view.

Kobayashi Pharmaceutical Co., Ltd. (4967.T) Revenue Analysis

• Reported revenue (FY2024): ¥165.6 billion (‑4.53% YoY)
• Primary negative driver: benikoji supplement health scare → recalls and ad suspension
• First profit decline since IPO in 1999
• Company response: new product launches and gradual resumption of advertising
• FY2025 revenue forecast: ¥171.0 billion (projected +3.3% YoY)

• Domestic sales: materially pressured by recall and negative publicity, reducing shelf presence and short‑term distributor orders.
• International sales: uneven trends-some markets held steady while others weakened due to demand shifts and risk‑averse buyers.
• Mitigants: pipeline of new SKUs, phased resume of advertising, targeted promotions to rebuild consumer trust.

Kobayashi Pharmaceutical Co., Ltd. (4967.T) - Profitability Metrics

Kobayashi Pharmaceutical's FY2024 profitability shows mixed signals: operating profitability remained positive while net earnings were severely impacted by an extraordinary recall-related charge.

• Operating income (FY ending Dec 31, 2024): ¥24.8 billion (-3.6% YoY)
• Net profit (FY ending Dec 31, 2024): ¥10.0 billion (-50.5% YoY)
• Extraordinary loss (FY2024): ¥12.7 billion, driving the net profit decline

The extraordinary loss comprised multiple large components:

• Recall of supplements: over ¥4.0 billion
• Recall and compensation for raw materials: over ¥4.0 billion
• Compensation for health damage: over ¥4.0 billion

Despite the sharp net profit decline driven by the ¥12.7 billion extraordinary loss, Kobayashi Pharmaceutical maintained positive net income and solid operating profitability metrics, reflecting operational resilience amid the recall-related disruptions. For broader strategic context see: Mission Statement, Vision, & Core Values (2026) of Kobayashi Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd. (4967.T) - Debt vs. Equity Structure

• Total debt to equity ratio: 0.38 (as of July 4, 2025) - indicates low leverage relative to equity.
• Current ratio: 3.34 - demonstrates robust short-term liquidity and an ability to cover current liabilities more than threefold with current assets.
• Cash and cash equivalents: ¥67.28 billion (most recent quarter) - a substantial cash cushion for operations, M&A, or capital allocation.
• Book value per share: ¥2,785.27 - reflects the company's net asset backing on a per-share basis.
• Enterprise value / Revenue: 2.07 - moderate top-line valuation multiple compared with industry peers.
• Enterprise value / EBITDA: 10.88 - suggests a reasonable earnings-based valuation, neither deeply discounted nor richly priced.
• Market capitalization: ¥395.48 billion (as of July 1, 2025) - market consensus of firm value given current performance and outlook.

• Balance sheet strength: Low debt-to-equity and high current ratio reduce bankruptcy and refinancing risk.
• Liquidity optionality: ¥67.28 billion in cash supports near-term investments, dividends, or buybacks without reliance on debt markets.
• Valuation context: EV/Revenue of 2.07 and EV/EBITDA of 10.88 place the stock in a moderate valuation band - attractive for risk-averse investors seeking stability rather than high-growth speculation.
• Shareholder protection: Book value per share of ¥2,785.27 offers a tangible floor for long-term equity value under liquidation or stress scenarios.

Kobayashi Pharmaceutical Co., Ltd. (4967.T) - Liquidity and Solvency

• Current ratio: 3.34 - well above typical industry benchmarks, signaling strong ability to meet short-term liabilities.
• Total debt to equity: 0.38 - indicates low financial leverage and a conservative capital structure.
• Cash & cash equivalents: ¥67.28 billion - ample liquid reserves for working capital and contingencies.
• Operating cash flow (TTM): ¥15.99 billion - solid cash generation from core operations.
• Levered free cash flow (TTM): ¥10.07 billion - positive post-capex and debt servicing cash available for dividends, buybacks or debt reduction.
• Book value per share: ¥2,785.27 - provides a measure of net asset value attributable to each share.

Kobayashi Pharmaceutical Co., Ltd. (4967.T) - Valuation Analysis

• Trailing P/E: 36.94 - elevated relative to historical averages, implying investors pay a premium for past earnings.
• Forward P/E: 22.53 - materially lower than the trailing P/E, reflecting expected earnings growth or normalization.
• Price-to-Sales (TTM): 2.45 - indicates a reasonable valuation versus revenues for a consumer-health company.
• Enterprise Value / Revenue: 2.07 - consistent with the price-to-sales view after accounting for debt and cash.
• Enterprise Value / EBITDA: 10.88 - a moderate multiple suggesting fair pricing on operating cash flow.
• Market capitalization: ¥395.48 billion (as of July 1, 2025) - a sign of solid market positioning.
• Book value per share: ¥2,785.27 - reflects the company's net asset backing per share.
• Dividend yield: 1.67% with a forward annual dividend of ¥88.00 per share - provides modest income to shareholders.

Kobayashi Pharmaceutical Co., Ltd. (4967.T) - Risk Factors

The following risk factors summarize the financial, legal, operational, and reputational exposures stemming from the 'benikoji' supplement health scare and its aftermath.

• Immediate financial impact: product recalls, direct compensation and recall logistics materially reduced profitability in the affected reporting period.
• Legal exposure: shareholder derivative litigation and potential class-action style claims increase contingent liabilities and legal expense volatility.
• Ongoing consumer compensation: negotiations and settlements with affected consumers create uncertain, continuing cash outflows.
• Regulatory pressure: heightened inspections, reporting requirements and potential sanctions raise compliance costs.
• Brand and revenue risk: diminished consumer trust threatens near- to mid-term sales in core supplement and OTC categories.

• Shareholder derivative lawsuit: Oasis Management Company Ltd. initiated a derivative suit alleging director-level mishandling of the 'benikoji' incident; potential governance remediation and board-level costs may follow.
• Reputational damage: media coverage and social amplification have driven measurable brand erosion, requiring marketing and trust-rebuilding investments.
• Operational disruption: recall logistics strained supply-chain and manufacturing schedules, leading to lost sales and overtime/outsourcing expenses.
• Insurance coverage uncertainty: portions of liability may be uninsured or disputed by carriers, increasing net cash exposure.
• Future product approval and launch delays: regulatory scrutiny can lengthen time-to-market for reformulated or replacement SKUs, delaying recovery of sales.

Key near-term metrics investors should monitor:

• Quarterly net profit and operating cash flow trends versus pre-incident baselines.
• Changes to provisions and contingent liability disclosures in quarterly/annual filings.
• Ongoing settlement payouts and consumer compensation program updates.
• Regulatory notices, fines, or mandated corrective actions disclosed by authorities.
• Sales recovery rates in core OTC and supplement categories and SKU-level restocking data.

For context on the company's stated long-term direction alongside these risks, see: Mission Statement, Vision, & Core Values (2026) of Kobayashi Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd. (4967.T) - Growth Opportunities

• New product launches and resumption of advertising: Several product lines have been relaunched with renewed promotional spend, supporting topline recovery after product-related setbacks.
• 2025 revenue outlook: Management forecasts a 3.3% revenue increase for FY2025 (year ending 31 Dec 2025), implying a modest but positive growth trajectory.
• Compensation and consumer relations: Ongoing compensation discussions with affected consumers are intended to repair trust and reduce long-term brand damage, potentially improving repeat purchase rates.
• Enhanced safety and quality control: Increased investment in QA/QC and supply-chain controls aims to reduce incident risk and protect brand equity.
• Market and channel expansion: The company is exploring new geographic markets and alternative distribution channels (including e-commerce and partnerships) to broaden market reach.
• R&D-led innovation: Continued spending on R&D to develop differentiated products positions the company to capture higher-margin opportunities and defend market share.

• Advertising and marketing: Gradual resume of ad campaigns is intended to restore brand visibility; metrics to watch include ad ROI, share-of-voice, and rate of sales recovery per SKU.
• Product pipeline: Ramped R&D activity targets both line extensions for fast time-to-market and higher-value proprietary products to improve gross margins.
• Distribution strategy: Expansion into new retail partners and intensified e-commerce presence could lower unit distribution cost and increase gross penetration.